AC Immune (ACIU) Stock Forecast & Price Target

AC Immune is attractive because its pipeline combines differentiated active immunotherapy, imaging, and oral anti-aggregation approaches across Alzheimer’s and Parkinson’s disease, giving it multiple shots on goal in high-need neurodegenerative markets. The week-100 VacSYn readout for ACI-7104 was especially encouraging, meeting all three primary endpoints with 100% responder rate, robust CSF penetration, and exploratory signals linking antibody titers to Nf-L stabilization, dopamine receptor function, and UPDRS-III improvement. Near-term value is further supported by ACI-24.060’s AD4 cohort initiation and a $12 million Takeda milestone, while the programs cited include estimated 2030 to 2031 market entries and substantial pricing power at $26,500 per patient per year in the U.S.

AC Immune is facing a weak fundamental setup because its key vaccine cohort appears unlikely to deliver a meaningful CNS antibody response, with serum-to-CNS translation described as only 0.1% to 0.5%, which raises doubts about whether the program can affect cognitive decline. The need for a higher dose and second adjuvant just to achieve a “plaque plucker’s chance” of efficacy underscores limited confidence in the therapeutic mechanism, while the absence of interim readouts leaves investors waiting for delayed validation. Although serum antibody levels may be known in a few months and the treatment period could extend to 18 months, the trial could still be stopped if induced antibody levels prove inadequate, reinforcing a negative outlook.